Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
Amarendra Pegu, Sarah O’Connell, Stephen D. Schmidt, et al.
Science (2021) Vol. 373, Iss. 6561, pp. 1372-1377
Open Access | Times Cited: 541

Showing 26-50 of 541 citing articles:

Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection
Ali Zhang, Hannah D. Stacey, Michael R. D’Agostino, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 6, pp. 381-396
Open Access | Times Cited: 126
Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization
Nicole A. Doria‐Rose, Xiaoying Shen, Stephen D. Schmidt, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 123
Robust induction of B cell and T cell responses by a third dose of inactivated SARS-CoV-2 vaccine
Yihao Liu, Qin Zeng, Caiguanxi Deng, et al.
Cell Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 122
COVID vaccine immunity is waning — how much does that matter?
Elie Dolgin
Nature (2021) Vol. 597, Iss. 7878, pp. 606-607
Open Access | Times Cited: 121
Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong
Qiaoli Peng, Runhong Zhou, Yuewen Wang, et al.
EBioMedicine (2022) Vol. 77, pp. 103904-103904
Open Access | Times Cited: 113
Theoretical basis for stabilizing messenger RNA through secondary structure design
Hannah K. Wayment-Steele, Do Soon Kim, Christian A. Choe, et al.
Nucleic Acids Research (2021) Vol. 49, Iss. 18, pp. 10604-10617
Open Access | Times Cited: 109
SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine
Ryutaro Kotaki, Yu Adachi, Saya Moriyama, et al.
Science Immunology (2022) Vol. 7, Iss. 70
Open Access | Times Cited: 109
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Benjamín L. Sievers, Saborni Chakraborty, Yong Xue, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 634
Open Access | Times Cited: 107
COVID-19 Vaccine Booster: To Boost or Not to Boost
Rahul Shekhar, Ishan Garg, Suman Pal, et al.
Infectious Disease Reports (2021) Vol. 13, Iss. 4, pp. 924-929
Open Access | Times Cited: 104
Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection
Yang Yang, Minghui Yang, Yun Peng, et al.
Nature Microbiology (2022) Vol. 7, Iss. 3, pp. 423-433
Open Access | Times Cited: 104
Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study
Massimo Fabiani, Maria Puopolo, Cristina Morciano, et al.
BMJ (2022), pp. e069052-e069052
Open Access | Times Cited: 98
Omicron variant (B.1.1.529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?
Manish Dhawan, AbdulRahman A. Saied, Saikat Mitra, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113522-113522
Open Access | Times Cited: 93
American College of Rheumatology Guidance for COVID‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5
Jeffrey R. Curtis, Sindhu R. Johnson, Donald D. Anthony, et al.
Arthritis & Rheumatology (2022) Vol. 75, Iss. 1
Open Access | Times Cited: 88
SARS-CoV-2: Evolution and Emergence of New Viral Variants
Verónica Roxana Flores-Vega, Jessica Viridiana Monroy-Molina, Luis Enrique Jiménez-Hernández, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 653-653
Open Access | Times Cited: 85
Antiviral Drug Discovery for the Treatment of COVID-19 Infections
Teresa I. Ng, Ivan Correia, Jane Seagal, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 961-961
Open Access | Times Cited: 77
Characterization of immune responses in fully vaccinated individuals after breakthrough infection with the SARS-CoV-2 delta variant
Ai‐ris Y. Collier, Catherine Brown, Katherine McMahan, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 641
Open Access | Times Cited: 75
Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2
Negar Firouzabadi, Parisa Ghasemiyeh, Fatemeh Moradishooli, et al.
International Immunopharmacology (2023) Vol. 117, pp. 109968-109968
Open Access | Times Cited: 74
A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
Zezhong Liu, Jie Zhou, Wei Xu, et al.
Cell Research (2022) Vol. 32, Iss. 3, pp. 269-287
Open Access | Times Cited: 71
Mutational cascade of SARS-CoV-2 leading to evolution and emergence of omicron variant
Kanika Bansal, Sanjeet Kumar
Virus Research (2022) Vol. 315, pp. 198765-198765
Open Access | Times Cited: 71
Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains
Baoling Ying, Bradley Whitener, Laura A. VanBlargan, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 630
Open Access | Times Cited: 69
A multitope SARS-CoV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants
Chang Yi Wang, Kao‐Pin Hwang, Hui-Kai Kuo, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 10
Open Access | Times Cited: 68
Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review
Nick Pooley, Salim S. Abdool Karim, Béhazine Combadière, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 2, pp. 367-387
Open Access | Times Cited: 63
Durability of immune responses to mRNA booster vaccination against COVID-19
Prabhu S. Arunachalam, Lilin Lai, Hady Samaha, et al.
Journal of Clinical Investigation (2023) Vol. 133, Iss. 10
Open Access | Times Cited: 54
Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
Spyros Chalkias, Jordan L. Whatley, Frank Eder, et al.
Nature Medicine (2023) Vol. 29, Iss. 9, pp. 2325-2333
Open Access | Times Cited: 44
Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine–boosted nonhuman primates
Kizzmekia S. Corbett, Matthew Gagné, Danielle A. Wagner, et al.
Science (2021) Vol. 374, Iss. 6573, pp. 1343-1353
Open Access | Times Cited: 99

Scroll to top